|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular and Interventional Radiology |
1 From the Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany. Received October 11, 2002; revision requested December 26; final revision received May 11, 2003; accepted June 9. Address correspondence to T.J.V. (e-mail: t.vogl@em.uni.frankfurt.de).
PURPOSE: To evaluate a treatment protocol with repeated transarterial chemoembolization (TACE) before laser-induced thermotherapy (LITT) in patients with unresectable liver metastases that are too large for LITT alone.
MATERIALS AND METHODS: One hundred sixty-two patients who had unresectable liver metastases, with the largest lesion as large as 80 mm in diameter, and no more than four lesions were treated with repeated TACE between March 1999 and December 2001. TACE was performed with a maximum of 10 mg/m2 mitomycin for chemotherapy and a maximum of 15 mL/m2 of iodized oil and microspheres for vessel occlusion. Tumor volume before and during treatment was measured at magnetic resonance (MR) imaging. If the diameter of the tumor decreased to less than 50 mm, the patients were treated with MR imagingguided LITT 46 weeks following embolization.
RESULTS: Eighty-two patients (62 with metastases from colorectal cancer, 14 with metastases from breast cancer, and six with metastases from other primary tumors) responded to TACE, with a mean reduction in tumor size of 35% ± 14 (SD), and were treated with LITT. Each patient underwent two to seven TACE treatments (mean, 4.3) prior to LITT. In 47 patients, no reduction in tumor size was achieved, which led to further follow-up. In 33 patients, disease progression was found, with either an increasing size of the lesions (n = 18) or newly developing metastases (n = 15), and these results led to further TACE treatments or change to systemic chemotherapy. Median survival of patients who responded to this combined treatment was 26.2 months; in patients treated with only TACE, median survival was 12.8 months (range, 0.329.4 months).
CONCLUSION: With repeated TACE, reduction in size of primary unresectable hepatic metastases is achieved in 50.6% of cases and allows local ablative treatments such as MR imagingguided LITT.
© RSNA, 2003
Index terms: Hepatic arteries, chemotherapeutic embolization, 761.1264, 761.1266, 952.1264, 952.1266 Interventional procedures, comparative studies, 761.1264, 761.1266 Lasers, interstitial therapy, 761.1269 Liver neoplasms, metastases, 761.33
This article has been cited by other articles:
![]() |
T. J. Vogl, T. Gruber, J. O. Balzer, K. Eichler, R. Hammerstingl, and S. Zangos Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study Radiology, January 1, 2009; 250(1): 281 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Pawlik, R. D. Schulick, and M. A. Choti Expanding Criteria for Resectability of Colorectal Liver Metastases Oncologist, January 1, 2008; 13(1): 51 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Liapi and J.-F. H. Geschwind Transcatheter and Ablative Therapeutic Approaches for Solid Malignancies J. Clin. Oncol., March 10, 2007; 25(8): 978 - 986. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |